Lisinopril
SIGMA/L6292 - ≥98% (HPLC)
Synonym: (S)
CAS Number: 83915-83-7
Empirical Formula (Hill Notation): C21H31O5N3 · 2H2O
Molecular Weight: 441.52
MDL Number: MFCD01698825
Linear Formula: C21H31O5N3 · 2H2O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white |
| form | solid |
| InChI | 1S/C21H31N3O5.2H2O/c22-13 |
| InChI key | CZRQXSDBMCMPNJ-ZUIPZQNBSA |
| Quality Level | 100 ![]() |
| SMILES string | [H]O[H].[H]O[H].NCCCC[C@H |
| solubility | DMSO: ~6.5 mg/mL (with heating and sonicating) |
| H2O: ≥10 mg/mL | |
| storage temp. | 2-8°C |
| Application: | Lisinopril has been used to study the antifibrotic effect in duchenne muscular dystrophy mice. It has been used to study the changes in renal-structure and -function in TGR(mRen2)27 (transgenic rat harboring the murine Ren-2 gene) rats upon long term darbepoetin α treatment. |
| Biochem/physiol Actions: | Angiotensin converting enzyme (ACE) inhibitor. |
| Features and Benefits: | This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S. . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 100, 250 mg in glass bottle |
| Symbol | GHS08 |
| Signal word | Danger |
| Hazard statements | H360 - H373 |
| Precautionary statements | P201 - P308 + P313 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |


